Background {#Sec1}
==========

STTR treatment cascade {#Sec2}
----------------------

The Seek, Test, Treat and Retain (STTR) treatment or HIV care cascade is a challenging yet potentially beneficial response to addressing HIV in an era of effective treatments \[[@CR1]--[@CR3]\]. This approach requires reaching out to at-risk individuals who have not been tested for HIV recently (Seek), engaging them in HIV testing (Test), initiating persons living with HIV (PLWH) on antiretroviral therapy (ART) and other treatment services (Treat), and facilitating uninterrupted HIV care (Retain) \[[@CR1], [@CR2]\]. The STTR treatment cascade provides a framework for research aimed at improving the delivery of services, care and outcomes of PLWH. There is substantial dropout across each cascade step, and it has been estimated that only \~19% of PLWH in the United States (US) are aware of their HIV diagnosis, engaged in care, on ART, and have an undetectable viral load (VL) \[[@CR1]\], although more recent numbers suggest improvements \[[@CR4], [@CR5]\]. The development of effective approaches to increase HIV diagnoses and engage PLWH in subsequent steps of the treatment cascade could lead to earlier and sustained ART treatment resulting in viral suppression. Improvements in the STTR treatment cascade have the potential to benefit the health of PLWH and improve public health by reducing HIV transmission \[[@CR2]\].

The relevance of understanding the STTR treatment cascade across all CJ settings {#Sec3}
--------------------------------------------------------------------------------

In the US, there are two main types of correctional facilities---jails, that typically are administered by city or county governments, and hold people awaiting trials or serving shorter sentences (generally under two years), and prisons that typically are administered by state and federal governments and hold people serving longer sentences or who have had their parole or probation revoked. Community supervision includes pretrial, probation and parole. Pretrial refers to people awaiting trial before receiving a criminal conviction or acquittal. Probation refers to adults who have been placed on supervision in the community, typically through local or state court systems; about half of individuals on probation also serve a short jail sentence. Parole refers to people who are released early from prison to serve the remaining part of their sentence in the community \[[@CR6]\]. The criminal histories of people in prison typically are more serious, lengthy, and varied than individuals in jail or on community supervision \[[@CR7], [@CR8]\].

Currently, \>95% of incarcerated individuals will be released and re-enter society with nearly 80% being released to parole supervision \[[@CR9]\]. About 1 in 35 adults in the U.S. are under CJ supervision, and the number is expected to continue to increase \[[@CR10]\]. This trend expands opportunities for HIV prevention and treatment, especially in the public health realm \[[@CR11]\]. Specifically, the estimated HIV prevalence among individuals incarcerated in the US prison system is 2-3 times higher than the general population \[[@CR12]--[@CR16]\]. These statistics translate to one in seven PLWH being incarcerated each year, a figure that rises to one in five PLWH who are African-American or Hispanic \[[@CR17]\]. Although HIV testing rates in federal and state prisons are generally high (71%), \[[@CR18], [@CR19]\] testing rates in jails are not (19%) \[[@CR18]\]. Because many CJ-involved individuals pass only through jail, it is likely that many who are infected will not be offered HIV testing \[[@CR18], [@CR20]\]. These individuals may not know their HIV status or their potential to transmit HIV \[[@CR21]\]. Lack of testing among this higher risk group, and early ART initiation for those who are infected, is a lost opportunity to improve individual and public health and decrease HIV transmission. Those with HIV who return to the communities where they may lack access to health care services, including screening and early diagnosis, are likely to receive HIV treatment only after the disease has progressed to advanced stages \[[@CR16], [@CR22]\]. As such, the Centers for Disease Control and Prevention (CDC) encourages more frequent HIV testing of persons within the CJ system, particularly those with drug-dependencies, because PLWH who learn their HIV status are less likely to spread HIV and more likely to seek medical treatment that can lower the potential for HIV transmission and reduce HIV-associated morbidity and mortality \[[@CR23], [@CR24]\]. Finally, while PLWH incarcerated in prisons have access to care, including ART, maintaining ART and other medical services is a significant challenge for many re-entering the community following incarceration in prison \[[@CR25]\] and engagement in the HIV care cascade has been shown to decline substantially after release \[[@CR26]\]. Effective interventions are essential to link individuals to appropriate post-incarceration care and enhance retention in HIV care. The CJ involvement makes this a particularly unique and important cohort for addressing key questions across the HIV treatment cascade.

Methods {#Sec4}
=======

Cohort development {#Sec5}
------------------

The STTR CJ cohort is the product of the STTR Data Collection and Harmonization Initiative developed by the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute on Drug Abuse (NIDA), the National Institute of Mental Health (NIMH), and the Office of AIDS Research (OAR). This cohort was developed by a collaboration with researchers who harmonized and pooled data from independent prospective research studies funded under a grant mechanism focused on enhancing the STTR treatment cascade for individuals involved with the CJ system across the US \[[@CR27]\]. This initiative produced another cohort not described here focused on vulnerable populations particularly substance users at risk for or with HIV in international and domestic settings. While the STTR initiative and its rationale have been previously described \[[@CR27]\], the cohort itself has not yet been described.

Cohort management structure {#Sec6}
---------------------------

The STTR CJ collaboration consists of a three way partnership between 1) individual researcher teams responsible for conducting the STTR studies and overseeing all enrollment and data collection; 2) a scientific officer and program officials from NIAID, NIDA, NIMH, and OAR who provide expertise and guidance regarding the data harmonization initiative; and 3) the STTR Data Coordination Center (DCC), which provides expertise in data harmonization, epidemiology, biostatistics, and HIV, harmonizes the data, supports investigations that use the harmonized data to answer novel scientific questions, and develops new methods for analysis of complex pooled data.

Cohort description {#Sec7}
------------------

The STTR CJ cohort is unique in its focus on data from individuals involved in the CJ system and includes 11 NIAID, NIDA, NIMH, and OAR funded studies, several of which involve multiple sub-components and embedded studies. It includes single and multi-site randomized controlled and observational trials evaluating interventions to enhance care delivery along the HIV treatment cascade. It provides a large sample across CJ settings (jail, prison, community supervision) and includes both PLWH and HIV-uninfected individuals, many of whom engage in illicit drug use. Compared to single studies, the CJ cohort data provide increased statistical power to determine public health benefits of the STTR paradigm, address research questions on specific groups at risk of exiting the treatment cascade, and improve understanding of the intersection of drug use and HIV treatment. This cohort profile describes data from the resulting cohort and individual CJ studies including baseline demographic and clinical characteristics.

Data harmonization {#Sec8}
------------------

Eleven domains were selected for data harmonization: CJ involvement; HIV risk behaviors; HIV and/or hepatitis C infection; laboratory measures of CD4+ cell count and HIV RNA viral load among those with HIV; mental health; health related quality of life; socioeconomic; health care access; substance use and alcohol use; and social support (Fig. [1](#Fig1){ref-type="fig"}). The goal is to integrate data from across studies to address research questions requiring sample sizes beyond that of a single study.Fig. 1STTR CJ domains selected for data harmonization

The DCC, with investigators from individual studies, is responsible for data integration. The DCC provides technical support and oversees a web-based project collaboration and document management system; documents procedures for data collection and translation, transmission, and quality control; develops integration methods; and generates analyzable data sets. Studies typically upload data biannually. The DCC coordinates data integration from studies sometimes collected using different instruments or timeframes to ensure that the data are comparable across studies in meaning and content. To accomplish this, an examination of data types collected by each study was conducted, working closely with individual study personnel to survey each study's protocol including how data were collected and modifications to the instruments used. Where data were comparable, codes were developed to create standardized sets of variables.

Availability of data and materials {#Sec9}
----------------------------------

The datasets generated during the current study are not publically available due to privacy/license concerns. However, we welcome collaboration from interested parties. We have policies to ensure multi-center analytic research proposals are developed and results analyzed collaboratively and fairly. We are guided by principles of other cohort collaborations \[[@CR28]--[@CR30]\] including that data at the DCC will be stripped of all protected health information (PHI); an individual study can choose to participate or not in any scientific aim or sub-aim; and concept proposals and completed manuscripts must be approved by the Publications and Presentations (P&P) committee. We appreciate and encourage mentorship and the use of the STTR data to enable early investigators to address meaningful questions with support to help ensure their success. Additional information can be obtained at the STTR website: <https://sttr-hiv.org/cms> or by contacting the STTR DCC at STTR\@uw.edu.

Results {#Sec10}
=======

Description of the STTR CJ studies and participants {#Sec11}
---------------------------------------------------

Figure [2](#Fig2){ref-type="fig"} shows the diverse geography of the participating studies. For each of the 11 studies and their substudies, the research topic, the components of the STTR treatment cascade addressed, and the targeted participants are described in Table [1](#Tab1){ref-type="table"}. All the steps of the treatment cascade are included in multiple studies, and a diverse array of research topics are included. The STTR CJ cohort includes studies focused on later steps in the STTR treatment cascade such as treatment and retention of PLWH and studies focused on earlier steps such as HIV testing. Therefore, the percentage of PLWH in the individual STTR CJ studies at baseline varies, ranging from 0 to 100% (Table [1](#Tab1){ref-type="table"}), with an overall baseline total of 1888 PLWH. For each of the 11 studies and their substudies, detailed inclusion and exclusion criteria, and the study design including whether it was observational or a trial is described in Table [2](#Tab2){ref-type="table"}. In addition to baseline information, most studies collected data at 3 and/or 6-month follow-up time points, and many include 12 month and other follow-up time points (Table [2](#Tab2){ref-type="table"}).Fig. 2STTR CJ participating sites Table 1Description of STTR CJ cohort studies including research topics, targeted study participants, and HIV status of participantsStudyEnrollment start dateTreatment cascadeResearch topicTargeted study participantsHIV, %BRIGHT BRIGHT 12011S, THIV testingOn probation or parole0.1 BRIGHT 22011Tr, RLinkage to HIV care via intensive CMHIV-infected; on probation or parole100CARE+ RCT2013Tr, RLinkage to HIV care via multi-component interventionHIV-infected; in jail or recently released100 HCV RIDOC2012S, TRapid HCV testing using pre-test video counselingShort-term detainees; unknown HCV statusN/A HCV PROB2014S, TRapid HCV testing using pre-test video counselingOn probation or parole; unknown HCV statusN/AIMPACT2012Tr, RLinkage to HIV care and engagement in clinical care via multi-component interventionHIV-infected inmates; RNA levels \<400 copies/mL, on ART; 3 months prior to prison release100LINK LA2012Tr, RLinkage to HIV care via peer-based interventionHIV-infected; in jail100NEW HOPE2011Tr, RMedication assisted treatment for substance abuseHIV-infected; opiate dependent; leaving prison & jail100STT2013S, T, Tr, RHIV testing and linkage to HIV careJail detainees0.4STT ILLINOIS OPT OUT2012S, THIV testingIn jailN/A CM JAIL2013Tr, RLinkage to, and retention in HIV care via transition CMHIV-infected; leaving jail100 CM PRISON2013Tr, RLinkage to, and retention in HIV care via transition CMHIV-infected; recently released from prison100START2011S, THIV testing and risk reductionSubstance users entering drug treatment programN/ASTRIDE STRIDE 12011Tr, RMedication assisted treatment for substance abuseHIV-infected; opiate dependent100 STRIDE 22014Tr, RMedication assisted treatment for substance abuseHIV-infected; opiate dependent100SUCCESS2014Tr, RLinkage to, and retention in, HIV care via intensive CMHIV-infected; jail detainees100UHS II UHS IIC2011S, THIV testingPeople who inject drugs or smoke crack cocaine3.3 UHS IIL2011Tr, RLinkage to and engagement in HIV care via CMPeople who inject drugs or smoke crack cocaine and have HIV100*ART* antiretroviral therapy, *CJ* criminal justice, *CM* case management, *N/A* not applicable, *HCV* hepatitis C virus, *HIV* human immunodeficiency virus, *R* retain, *RNA* ribonucleic acid, *S* seek, *STTR* seek, test, treat and retain, *T* test, *Tr* treat, *US* United States Table 2Study design, follow-up, and participant criteria for STTR CJ cohort studiesStudy^a^Study designFollow-up time pointsIndividual inclusion and exclusion criteriaBRIGHT BRIGHT 1Randomized/observational study of on-site rapid HIV testing at probation/parole office vs. off-site referral at a community health centerBaseline onlyUnknown HIV status; on probation or parole in Baltimore, MD or Providence/ Pawtucket, RI and residence in the Baltimore or Providence/Pawtucket area throughout the study period BRIGHT 2RCT of case management (Project Bridge) vs. TAU3,6,12,15,18 monthsHIV-infected; on probation or parole in Baltimore, MD and planned residence in greater Baltimore area throughout the study periodCARE+ RCTRCT of CARE+ Corrections interventionMonthly for 24 monthsAged 18+; HIV-infected; released from the correctional facility or half-way house ≤6 months ago and living in Washington, DC metropolitan community (not a restricted setting, e.g. half-way house) or currently detained in jail with anticipated release to community (not a restricted setting); reading at 8th grade level and English-speaking HCV RIDOCCross-sectional study of HCV testingBaseline onlyAged 18+; self-reported as HCV negative and documented HCV infection during Department of Corrections time with anticipated release between 3 and 12 weeks from enrollment; English-speaking HCV PROBCross-sectional study of HCV testingBaseline onlyAged 18+; self-reported as HCV negative or unknown; on probation or parole; English speakingIMPACTRCT of IMPACT intervention vs. standard of care2, 6, 14, and 24 weeksAged 18+; HIV-infected with HIV RNA \< 400 copies/mL receiving ART who were incarcerated in NC or TX and 3 months prior to release and not convicted of sexual assault, death or serious injury; English-speakingLINK LARCT of intervention2, 6, 12 monthsMale or transgender individuals, aged 18+; HIV infected; incarcerated in a single facility for 5+ days; residing in Los Angeles County, CA upon release; English fluencyNEW HOPEPlacebo-controlled RCT of. extended-release naltrexoneMonthly for 12 monthsAged 18+, HIV-infected, meeting DSM-IV criteria for opioid dependence, within CT corrections system and not pending trial for a felony, within 30 days of being released to greater New Haven, Hartford, Waterbury or Springfield areas or 30 days after release; English- or Spanish-speaking, no liver failure or grade IV hepatitis, no active opioid withdrawal, no receipt of methadone or buprenorphine/naloxone for treatment of opioid dependency, no participation in pharmacotherapy trial in the previous 30 daysSTTObservational study of comprehensive Seek Test Treat strategies with medical record linkage 2 years post-release2 yearsAged18+; admitted to a detention facility, expected to be released to Milwaukee County, WI who were willing to be tested for HIV; verbal communication in EnglishSTT ILLINOIS OPT OUTCross-sectional study of opt-out HIV testingBaseline onlyAged 18+; detained in the IL corrections system CM JAILNon-randomized study of case-management intervention vs. standard of care6, 12, 18 monthsAged 18+; HIV-infected; detained in IL corrections system (jail); expecting to reside in Chicago after release CM PRISONNon-randomized study of case-management intervention vs. standard of care6, 12, 18 monthsAged 18+; HIV-infected; recently released from IL corrections system (prison); enrollment was within 60 days of releaseSTART1. RCT of CARE-Rapid (computer-assisted program) vs. TAU and 2. quasi-experimental study of manualized intervention vs. TAU, with follow-up at 3 months3 monthsMen aged 18+ with either unknown or believed negative HIV status within 90 days of release from NY detention center entering a residential substance abuse treatment programSTRIDE STRIDE 1RCT of buprenorphine vs. placeboMonthly for 12 monthsAged 18+; HIV-infected; meeting DSM-IV criteria for opioid dependence; resident of Washington, DC with eligibility for medical entitlements; English- or Spanish-speaking; no current opiate medications for chronic pain conditions or need to be placed on such medications; no current methadone doses over 30 mg/day, no AST and ALT \>5× the ULN; no pregnancy or breast-feeding; no liver dysfunction; no suicidal ideation; no participation in pharmacotherapy trial in the previous 30 days STRIDE 2Longitudinal cohort study comparing treatment using opioid substitution therapy to no treatment3, 6, 9, 12 monthsAged 18+; HIV-infected; meeting DSM-IV criteria for opioid dependence; resident of Washington, DC with eligibility for medical entitlements; English-speakingSUCCESSNon-randomized pilot study of Strengths-Based case management and texting3, 12 monthsAged 18+; HIV-infected; detained or sentenced in jail or detention center and likely to leave within 6 weeks; no recent participation in randomized trial to improve retention in HIV care; English-speakingUHS IIUHS IICCross-sectional study of HIV testingBaseline onlyAged 18+; crack cocaine or injection drug use in the past 30 daysUHS IILLongitudinal cohort study of case management (Project Bridge) vs. usual treatmentQuarterly for 24 monthsAged 18+; HIV-infected; crack cocaine or injection drug use in the past 30 days*ALT* alanine aminotransferase, *ART* antiretroviral therapy, *AST* aspartate aminotransferase, *CA* California, *CJ* criminal justice, *CT* Connecticut, *DC* District of Columbia, *DSM-IV* Diagnostic and Statistical Manual of Mental Disorders IV, *HCV* hepatitis C virus, *HIV* human immunodeficiency virus, *IL* Illinois, *MD* Maryland, *NC* North Carolina, *NY* New York, *RCT* randomized controlled trial, *RI* Rhode Island, *RNA* ribonucleic acid, *TAU* treatment as usual, *TX* Texas, *ULN* upper limit of normal, *WI* Wisconsin^a^Study acronyms as in Table [1](#Tab1){ref-type="table"}

The STTR CJ cohort includes 11,070 individuals with and without HIV who range in age from 18 to 77 years with a median baseline age of 37 years. The STTR CJ cohort is diverse and includes substantial numbers of African-American (64%) and Hispanic (12%) individuals as well as 17% percent women (Table [3](#Tab3){ref-type="table"}). Given differences in enrollment criteria across STTR CJ cohort studies, the percentage reporting HIV risk behaviors varies considerably (Table [4](#Tab4){ref-type="table"}). Injection drug use (IDU) ranged from 86% of participants reporting ever use in one study, with 64% in that study reporting IDU within the 30 days prior to incarceration, to very low levels in other studies (Table [4](#Tab4){ref-type="table"}). Reports of recent condomless anal or vaginal intercourse also varied from 4 to 79% of participants. Recent use of marijuana, cocaine, and opioids, and binge drinking were common across all studies (Table [5](#Tab5){ref-type="table"}) with 53% reporting use of multiple substances. Information regarding nonmedical prescriptions drug use is available from 9 of the studies and substudies. The participants were recruited from a wide range of CJ settings including jail, prison, and community supervision (pretrial, parole and probation) with particularly large numbers of individuals from jail, prison, and probation (Table [6](#Tab6){ref-type="table"}).Table 3Demographic characteristics for STTR CJ cohort study participantsRace/ethnicity, %Self-identified gender, %Study^a^N^b^American Indian or Alaskan NativeAsianBlack or African AmericanNative Hawaiian or Other Pacific IslanderWhiteHispanic or LatinoSome other raceTwo or more racesDon't know, refused, missingFemaleMaleTrans-genderDon't know, refused, missingAge, median years (range)BRIGHT BRIGHT 124052.40.051.60.028.012.81.53.60.117.882.10.20.039 (18-73) BRIGHT 21001.00.090.00.03.03.00.03.00.022.078.00.00.045 (28-70)CARE+ RCT1120.00.086.60.03.60.90.98.00.028.657.112.51.842 (19-63) HCV RIDOC2504.81.214.80.046.822.42.08.00.06.493.60.00.031 (19-58) HCV PROB1384.40.018.80.741.325.42.25.81.518.880.40.70.032 (19-68) IMPACT3812.10.066.10.019.78.10.83.20.022.075.32.40.344 (20-64) LINK LA3561.10.834.61.121.931.20.88.50.03.684.511.00.040 (21-69) NEW HOPE1230.00.022.80.012.263.40.00.80.817.981.30.80.046 (21-67) STT39631.40.263.20.114.69.40.55.94.72.996.90.10.129 (18-73)STT ILLINOIS OPT OUT2360.40.067.80.09.720.30.90.90.056.843.20.00.027 (18-60) CM JAIL3761.10.381.40.07.79.00.00.50.017.679.82.70.043 (18-74) CM PRISON900.00.090.00.03.35.60.00.01.18.986.73.31.1146 (19-64) START1951.00.546.20.021.629.20.51.00.00.01000.00.038 (19-65)STRIDE STRIDE 1500.00.090.00.00.02.00.04.04.028.068.02.02.053 (39-67) STRIDE 21090.00.096.30.01.80.90.00.00.946.845.97.30.051 (23-66) SUCCESS560.00.069.70.08.93.60.07.110.77.189.33.60.038 (21-58)UHS II UHS IIC20900.60.186.00.34.76.80.21.20.241.058.80.20.049 (18-77) UHS IIL482.10.083.30.04.26.30.04.20.029.260.410.40.047 (27-66)CJ, criminal justice; STTR, seek, test, treat and retain^a^Study acronyms as in Table [1](#Tab1){ref-type="table"}^b^There are 33 participants who are included in more than one sub-study: 3 in BRIGHT 1 and BRIGHT 2, and 30 in UHSIIC and UHSIIL Table 4Risk behavior characteristics for STTR CJ cohort study participantsInjection drug use, %^c^Shared injection equipment, %^c^Condomless sex, %^c^Study^a^N^b^Ever use: yesEver use: don't know, refused, missingRecent use: yesRecent: don't know, refused, missingRecent useRecent use: don't know, refused, missingRecentRecent: don't know, refused, missingBRIGHT BRIGHT 1240522.40.044.312.31.112.349.912.7 BRIGHT 210051.010.02.016.01CARE+ RCT11214.31.84.56.33.65.478.63.6 HCV RIDOC25017.610.04.4− HCV PROB13813.04.41.5− IMPACT381−−−− LINK LA356−−−54.83.7 NEW HOPE12386.23.364.23.317.94.925.23.3 STT396310.50.86.11.23.90.949.110.8STT ILLINOIS OPT OUT236−7.6−− CM JAIL376−8.00.32.70.328.52.7 CM PRISON90−8.91.13.31.138.91.1 START195−3.6−25.10.5STRIDE STRIDE 15076.04.034.04.04.08.04.06.0 STRIDE 210949.515.63.70.917.46.4 SUCCESS56−10.7−51.83.6 UHS II UHS IIC209043.026.5−64.50.05 UHS IIL4837.522.952.1*CJ* criminal justice, *STTR* seek, test, treat and retain^a^Study acronyms as in Table [1](#Tab1){ref-type="table"}^b^There are 33 participants who are included in more than one sub-study: 3 in BRIGHT 1 and BRIGHT 2, and 30 in UHSIIC and UHSIIL^c^Reference periods differed across studies; 30 days: STRIDE 1, NEWHOPE, START, SUCCESS, 90 days: BRIGHT 1 and 2, STRIDE 2, all STT Illinois studies, CARE + HCV RIDOC, CARE + RCT, STT, 180 days: LINK LA, UHS II. The following studies measured pre-incarceration risk behaviors: CARE+ RCT, CARE+ HCV RIDOC, LINK LA, NEW HOPE, STT, STT ILLINOIS OPT OUT, STT ILLINOIS CM JAIL, and STT ILLINOIS CM PRISON Table 5Substance use distribution for STTR CJ study participantsAlcohol use, %^c,e^Substance use, %^d,e^Multiple substance use, %^d,e^Study^a^N^b^AnyBingeMarijuanaCocaineOpioidsStimulantsOther≥2 substances (including alcohol)BRIGHT BRIGHT 1240548.228.727.510.713.00.32.929.9 BRIGHT 210044.025.022.026.023.01.03.038.0CARE+ RCT11280.460.735.737.517.08.920.554.5 HCV RIDOC25071.660.460.824.831.29.222.066.8 HCV PROB13863.837.042.015.910.92.94.439.1 IMPACT−−−−−−−−− LINK LA35653.124.754.217.110.158.19.866.3 NEW HOPE12337.422.823.677.291.90.88.981.3 STT396346.531.437.714.813.89.814.438.9STT ILLINOIS OPT OUT−−−−−−−−− CM JAIL37671.049.545.039.132.514.110.465.7 CM PRISON9075.653.363.344.441.113.313.377.8 START19572.853.935.921.521.01.012.347.2STRIDE STRIDE 15058.022.06.024.092.00.06.058.0 STRIDE 210962.433.024.841.383.56.411.069.7 SUCCESS5671.448.251.848.225.021.41.857.1UHS II UHS IIC209079.754.661.790.847.310.612.092.3 UHS IIL4864.639.666.766.722.96.38.372.9*CJ* criminal justice, *STTR* seek, test, treat and retain^a^Study acronyms as in Table [1](#Tab1){ref-type="table"}^b^There are 33 participants who are included in more than one study: 3 in BRIGHT 1 and BRIGHT 2, and 30 in UHSIIC and UHSIIL^c^Alcohol reference periods differed across studies; 30 days: LINK LA, NEW HOPE, START; UHS II; 90 days: BRIGHT 1 and 2, STT; 180 days: STT Illinois; 1 year: CARE + RCT, SUCCESS; not specified: STRIDE 1 and 2, START^d^Substance reference periods differed across studies; 30 days: LINK LA, NEW HOPE, START Together; STRIDE 1, SUCCESS, UHS II; 90 days: BRIGHT 1 and 2, CARE+ RCT and HCV RIDOC, STT Strategies, STRIDE 2; 180 days: STT Illinois^e^The following studies measured pre-incarceration alcohol and substance use: CARE+ RCT, CARE+ RIDOC, LINK LA, NEW HOPE, STT, STT JAIL, STT PRISON, and SUCCESS Table 6Supervision status for STTR CJ cohort study participantsCJ supervision status, %Study^a^N^b^No current CJ supervisionJailPrisonProbationParoleProbation/paroleOtherDon't know, refused, missingBRIGHT BRIGHT 1240500081.315.23.500.08 BRIGHT 210000069.025.06.000CARE+ RCT−−−−−−−−− HCV RIDOC2500010000000 HCV PROB13800097.80.70.700.7 IMPACT3810010000000 LINK LA3560100000000 NEW HOPE1230.058.527.63.30.80.05.74.1 STT39630100000000STT ILLINOIS OPT OUT2360100000000 CM JAIL3760100000000 CM PRISON9014.40.00.00.078.94.41.11.1 START−−−−−−−−−STRIDE STRIDE 15044.00.00.016.030.04.04.02.0 STRIDE 210978.90.00.03.710.10.06.40.9 SUCCESS560100000000UHS II UHS IIC209068.00023.56.12.100.2 UHS IIL4852.10035.44.28.300*CJ* criminal justice, *STTR* seek, test, treat and retain^a^Study acronyms as in Table [1](#Tab1){ref-type="table"}.^b^There are 33 participants who are included in more than one study: 3 in BRIGHT 1 and BRIGHT 2, and 30 in UHSIIC and UHSIIL

Harmonization results {#Sec12}
---------------------

By combining data across multiple studies, we include individuals involved with varying aspects of the CJ system, enabling comparisons that cannot typically be done within individual studies. For example, harmonizing data enables analyses involving subgroups such as transgender individuals and other subgroups that are often too small to assess in individual studies.

A key finding from our conduct of data harmonization is the need for multiple approaches. One technique involved modern psychometric approaches such as item response theory (IRT) to co-calibrate scales. Co-calibration enables people from studies who responded to different instruments to have scores that are "calibrated together" on a single common metric. IRT provides a suite of tools to model and account for measurement precision. We use this approach to address differences in the depression and anxiety measures across studies. In contrast, we found a different approach was needed to harmonize domains like ART adherence, which are behavioral rather than latent traits. Below we describe two harmonization efforts for ART adherence and risk behaviors.

Harmonization of ART adherence measures {#Sec13}
---------------------------------------

We used CJ studies that measured ART adherence with both the AIDS Clinical Trials Group (ACTG) questionnaire and the Visual Analogue Scale (VAS) measure to develop rules and a formula to co-calibrate both instruments. By co-calibrating adherence items from the ACTG (7 day recall) with the VAS, we were able to harmonize studies having different approaches to measuring adherence \[[@CR31]\]. We found that 44% of PLWH in the STTR CJ cohort who were on ART reported adherence rates \<95% for the prior 30 days and 38% reported having missed one or more doses in the prior 14 days. Furthermore, we found important variations not only in ART adherence in different groups, but also in how adherence measures work. The findings also highlighted problems with the VAS as a single item adherence measure and showed its validity varied across groups. These results would not have been feasible within single studies but instead were possible by harmonizing multiple studies to gain both necessary sample size and variation \[[@CR32]\].

HIV sexual risk behavior harmonization {#Sec14}
--------------------------------------

Eight studies administered a standardized risk behavior assessment tool to evaluate sexual risk behaviors in these reference periods: 30 or 90 days prior to incarceration for jail and prison detainees, or the previous 30 or 90 days for participants enrolled in the community. We described sexual risk behaviors of HIV-infected and uninfected participants in these studies and compared men and women \[[@CR33], [@CR34]\]. To test for differences in risk behaviors between men and women, we performed individual patient data meta-analysis to combine information across studies. Findings indicated a high prevalence of condomless anal or vaginal sex among PLWH and uninfected participants, particularly women with HIV. For example, the adjusted odds ratio for condomless sex was 1.84 (1.16-2.95) for women with HIV compared with men with HIV \[[@CR34]\]. By aggregating data across studies, we were able to overcome the much lower prevalence of women in CJ populations and, in turn, in each of the individual CJ studies.

Discussion {#Sec15}
==========

STTR CJ is a unique cohort that combines data from 11 studies that together address steps across the HIV treatment cascade focusing on participants with CJ involvement. The STTR CJ cohort includes a large and diverse assemblage of individuals who are at risk for, or living with HIV. The pooled data cohort is a sample of men, women, and transgender individuals across different racial/ethnic groups in multiple CJ settings (prison, jail, pre-trial, community supervision) as well as participants with no CJ involvement. The intervention studies span the HIV treatment cascade and have broad geographic locations across the US with participants enrolled from 11 states and the District of Columbia. These characteristics provide the opportunity to address questions of great importance for HIV prevention and treatment particularly related to individuals involved in the CJ system, those at risk or with HIV and using substances, and the unique risks and clinical needs of specific subgroups. For example, we are particularly interested in understanding the impact of changes in the intensity of substance use on HIV care cascade outcomes such as viral suppression and adherence, the impact of incarceration and release on the HIV care continuum, and to better understand risk behaviors of individuals upon release from incarceration. Finally, the study investigators and DCC have expertise in clinical, epidemiologic, CJ, biostatistical, and data harmonization areas. This team is well-positioned to address trans-disciplinary scientific questions and identify new questions that will arise as HIV care and prevention continues to evolve, and we have developed harmonized measures to allow for combining studies to answer these questions.

There are limitations to the STTR CJ cohort data. Some of these limitations are inherent in combining data from independent studies with different enrollment criteria and different study designs. While the STTR CJ cohort includes a large number of CJ-involved PLWH or persons at risk of HIV, this combination of studies is not a representative sample of those involved in the CJ system in the US, and in particular may underrepresent rural areas. Harmonization of some variables has been difficult due to modifications made by some individual studies to standardized instruments and data collection timeframes. For example, some studies modified timeframes for behaviors that were assessed (30 days vs. 90 days) to fit their study follow-up periods. Missing data varied by participating study and some studies have limited or no data on certain domains. This means that it is not feasible to use all studies in some analyses. For example, studies varied in whether they focused on current substance use or included type of substances at the time of incarceration. HIV status also varied with studies focused on later stages in the HIV cascade more likely focusing on PLWH. Similarly, studies that focused on late stages of the cascade cannot contribute to HIV risk analyses in that all participants are PLWH. The heterogeneity of study designs in the participating studies including both observational and interventional studies makes it feasible to study all the different stages of the STTR cascade but also complicates approaches to combining studies. When merging these studies it is critical to identify the subset of the STTR CJ cohort appropriate for and able to provide data on the research questions of interest. These studies recruited from diverse source populations. For example, two studies recruited participants who were at high risk of CJ system involvement but not necessarily already involved with the CJ system at baseline. This variation prevents the naïve pooling of studies, as baseline characteristics are different between studies, and requires clustering of participants by study be accounted for using a mixed model or generalized estimating equation approach. Longitudinal follow-up duration and frequency varies with several studies having limited follow-up time although we will continue to include all additional data collected over follow-up, so long as studies remain ongoing. While this variation limits power for analyses looking at longitudinal outcomes, the STTR CJ cohort remains better powered than individual studies.

The STTR CJ cohort is designed to allow expansion for new studies and domains as needed to address important questions in the HIV research agenda particularly related to the STTR treatment cascade. New studies will be added as needed to increase demographic, geographic, or clinical diversity and broaden scientific expertise. The STTR CJ cohort welcomes collaboration from interested parties and has policies to ensure multi-center analytic research proposals are developed and results analyzed collaboratively and fairly.

Conclusions {#Sec16}
===========

This cohort provides a large study sample across different CJ settings (jail, prison, community supervision) and includes both persons with and without HIV, many of whom engage in illicit drug use. Compared to single studies, the combined data of the CJ cohort provides increased statistical power to determine the public health benefit of the STTR paradigm, address research questions on specific groups at risk of exiting the treatment cascade, and improve understanding of the intersection of drug use and HIV treatment.
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